Your browser doesn't support javascript.
loading
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study.
Meric-Bernstam, Funda; Sweis, Randy F; Kasper, Stefan; Hamid, Omid; Bhatia, Shailender; Dummer, Reinhard; Stradella, Agostina; Long, Georgina V; Spreafico, Anna; Shimizu, Toshio; Steeghs, Neeltje; Luke, Jason J; McWhirter, Sarah M; Müller, Thomas; Nair, Nitya; Lewis, Nancy; Chen, Xinhui; Bean, Andrew; Kattenhorn, Lisa; Pelletier, Marc; Sandhu, Shahneen.
Afiliación
  • Meric-Bernstam F; The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sweis RF; The University of Chicago, Chicago, Illinois.
  • Kasper S; University Hospital Essen, West German Cancer Center, Essen, Germany.
  • Hamid O; The Angeles Clinic and Research Institute, A Cedars Sinai Affiliate, Los Angeles, California.
  • Bhatia S; University of Washington, Seattle, Washington.
  • Dummer R; Universitaetsspital Zuerich Dermatology, Zurich, Switzerland.
  • Stradella A; Institut Català d'Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Catalunya, Spain.
  • Long GV; Melanoma Institute Australia, The University of Sydney, and Mater and Royal North Shore Hospitals, Sydney, Australia.
  • Spreafico A; Princess Margaret Cancer Centre, Toronto, Canada.
  • Shimizu T; National Cancer Center Hospital, Tokyo, Japan.
  • Steeghs N; Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Luke JJ; The University of Pittsburgh, Pittsburgh, Pennsylvania.
  • McWhirter SM; Aduro Biotech, Inc., Berkeley, California.
  • Müller T; Aduro Biotech, Inc., Berkeley, California.
  • Nair N; Aduro Biotech, Inc., Berkeley, California.
  • Lewis N; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Chen X; Novartis Institutes for BioMedical Research, East Hanover, New Jersey.
  • Bean A; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Kattenhorn L; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Pelletier M; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Sandhu S; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Australia.
Clin Cancer Res ; 29(1): 110-121, 2023 01 04.
Article en En | MEDLINE | ID: mdl-36282874
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Linfoma / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Primarias Secundarias / Linfoma / Neoplasias Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article